（央视财经《经济信息联播》）在生物医药领域，部分国产创新药在疗效上展现出了能媲美 国际药企 明星药品的表现。近年来，有越来越多的国际制药企业斥巨资和中国药企展开合作。 今年年初，中国的人工智能模型DeepSeek以极低的开发成本和强大的性能获得了世界的瞩目，而其实 在生物技术领域，中国也正在迎来类似的"DeepSeek时刻"，中国药企正在从过去的仿制药时代进入到创 新药时代，并且吸引了众多的国际合作。合作的主要形式是授权合作：外方获得在中国以外市场对中方 药品或相关技术，开发、生产及商业化权利。 宏观上来看，美国生物医药数据公司DealForma在今年5月份发布的报告显示：中国生物医药企业在全球 大型授权交易，也就是首付款达到5000万美元或以上的交易中，按数量看占比已达42%，这一比例与去 年的27%和前年的20%相比显著增加。 一些亮眼案例，就例如今年5月辉瑞支付了12.5亿美元的首付款，获得了三生制药一款创新药在海外市 场的授权。此外，今年上半年，美国制药公司艾伯维、默沙东和再生元等和中国药企总计签署了价值数 十亿美元的授权合作协议。 值得一提的是药企阿斯利康，在过去两年间已和十多家中国创新药企达成了授 ...

Core Insights - China's innovative drug sector is experiencing explosive growth, with overseas licensing transaction amounts significantly increasing [1] - In the first half of this year, the transaction amount for innovative drug licensing has already exceeded $66 billion, surpassing the total for the entire previous year [1] - The emergence of AI model DeepSeek has drawn global attention, paralleling the advancements in China's biotechnology sector, marking a transition from generic drugs to innovative drugs [1] Industry Developments - Chinese pharmaceutical companies are attracting numerous international collaborations, indicating a shift in the global perception of China's drug innovation capabilities [1] - Notable partnerships include Pfizer's payment of $1.25 billion for the overseas licensing of an innovative drug from 3SBio in May [1] - Major US pharmaceutical companies such as AbbVie, Merck, and Regeneron have signed licensing agreements worth billions with Chinese firms in the first half of this year [1]

Group 1 - The core viewpoint is that the subscription model for cloud vendors' future business development is closely related to customer needs and industry strategies [1] - Currently, most cloud products are charged based on usage, including storage, computing, and bandwidth [1] - There is a challenge in implementing a performance-based payment model for marketing cloud services due to the numerous factors influencing marketing outcomes [1] Group 2 - The strategic choices made by the company are centered around user needs, focusing on identifying pain points and providing effective solutions [2] - The company has embraced the DeepSeek model in response to strong user interest, indicating a commitment to addressing real user demands [2] - The company will continue to adopt a multi-modal strategy based on user needs, ensuring that the best technology solutions are provided to customers [2]

Core Insights - Alibaba has open-sourced its first deep research Agent model, Tongyi DeepResearch, which has achieved state-of-the-art (SOTA) results on multiple authoritative evaluation sets, surpassing models from OpenAI and DeepSeek [1][2] - The model, framework, and solutions of Tongyi DeepResearch are fully available for users to download on platforms like Github, Hugging Face, and Modao Community [1] - The Tongyi team has developed a complete training pipeline driven by synthetic data, addressing challenges such as "cognitive space congestion" and "irreversible noise pollution" that affect long-term task processing [1] Performance Metrics - Tongyi DeepResearch model, with 3 billion activation parameters, outperforms flagship models like OpenAI o3, DeepSeek V3.1, and Claude-4-Sonnet across various benchmarks [2] - In the Humanity's Last Exam benchmark, Tongyi DeepResearch achieved a score of 32.9, significantly higher than competitors such as DeepSeek V3.1 (29.8) and OpenAI o3 (24.9) [2] - The model also excelled in other benchmarks, including BrowseComp-ZH (43.4), GAIA (46.7), and WebWalkerQA (70.9), showcasing its superior performance [2]

Core Insights - Doubao has surpassed DeepSeek in monthly active users, achieving a growth rate of 6.6% to reach 157.42 million users, reclaiming the top position among native apps [1] - Tencent Yuanbao recorded the highest growth rate among native apps at 22.4%, with a user base between 10 million and 100 million [1] Summary by Category Monthly Active Users - Doubao's monthly active user count reached 157.42 million, marking a 6.6% increase [1] - DeepSeek experienced a decline of 4.0% in its user base, ranking second [1] - Tencent Yuanbao ranked third in the top 10 native apps with a significant growth of 22.4% [1] Ranking Changes - Doubao moved up one position to reclaim the top spot among native apps [1] - DeepSeek dropped in ranking, now positioned at 2nd place [1] - Tencent Yuanbao's growth allowed it to enter the top 10 list [1] User Scale and Growth - Doubao is categorized in the "billion-level" user scale [1] - Tencent Yuanbao is classified within the "10 million to 100 million" user scale [1] - Other apps in the top 10 experienced varying degrees of user growth and decline, with some like Kimi and Doubao Aixue showing negative growth [1]

| | | | | 2025年8月 月活跃用户规模 TOP10 原生App 环比变化 (互联网/A科技企业) | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 序号 | 应用名称 | Alziń | 应用规模(万) | 规模量级 | 环比增速 | 排名变化 | Ар 规模量级变化 | | 1 8 豆包 | | Al综合助手 | 15,742 | 亿级 | 6.6% | 1 1位 | . | | 2 | Or DeepSeek | Al搜索引擎 | | 亿级 | -4.0% | 图 1位 | | | 3 6) 腾讯元宝 | | AI综合助手 | | 1000万-1亿 | 22.4% | .. | .. | | 4 | K Kimi | AI综合助手 | | 500-1000万 | -9.6% | | 工下降一个量级 | | 5 | A 即梦Al | Al创作设计 | | 500-1000万 | 10.8% | - | | | 6 | 2 豆包爱学 | Al学博教育 | | 500-1000万 | -7.0% | | | | 7 | C2 快对 ...

Core Insights - The report highlights the active user scale and growth rates of the top 10 native AI applications as of August 2025, showcasing significant changes in user engagement and rankings among these applications [1] Group 1: User Scale and Growth - The leading application, "豆包," has an active user scale of 15,742 million, representing a growth rate of 6.6% and an increase in ranking by one position [1] - "DeepSeek," an AI search engine, experienced a decline in user scale, with a decrease of 4.0%, resulting in a drop of one position in the rankings [1] - "腾讯元宝," another AI comprehensive assistant, recorded a user scale between 10 million and 100 million, with a notable growth rate of 22.4% [1] Group 2: Ranking Changes - "AQ," an AI professional consultant, saw a remarkable increase in user scale by 60.1%, which led to a rise of four positions in the rankings [1] - Other applications such as "K Kimi" and "豆包爱学" faced declines in user scale, with decreases of 9.6% and 7.0% respectively, indicating a downward trend in their rankings [1] - "文小言" and "快对AI" also experienced slight declines in user scale, with growth rates of -1.6% and -6.5% respectively, reflecting challenges in maintaining user engagement [1]

Core Viewpoint - The Sci-Tech Innovation Board (STAR Market) has successfully created a multi-path listing approach for unprofitable companies, allowing them to access capital markets without the traditional profit threshold, thus promoting the transformation of R&D capabilities into operational performance and industrial value [1][2]. Group 1: Listing Standards - The STAR Market has five sets of listing standards, with the second to fifth sets not requiring profit, instead focusing on revenue scale and R&D intensity, cash flow, and market capitalization [2]. - The second to fourth sets cater to "hard technology" companies with characteristics such as R&D strength and stable business models, while the fifth set evaluates companies based on market capitalization and developmental achievements, suitable for innovative firms with clear market prospects [2][4]. Group 2: Performance of Unprofitable Companies - Among the 54 unprofitable companies listed, 40% have achieved profitability, with a total revenue of 1,745 billion yuan in 2024, marking a 24% year-on-year increase, and a net loss of 136 billion yuan, reduced by 36% [3]. - By the first half of 2025, these companies reported a revenue of 999 billion yuan, an 8% increase year-on-year, with a net loss of 15 billion yuan, a 70% reduction compared to the previous year [3][6]. Group 3: Industry Innovations - Leading companies like Cambricon and SMIC are driving significant advancements in the semiconductor sector, enhancing the self-sufficiency of the supply chain and breaking foreign monopolies [4]. - The fifth set of standards has enabled unprofitable companies to transition into a new phase of commercial development, with 46 drugs/vaccines approved for market, including 20 innovative drugs that have not been previously launched domestically or internationally [4]. Group 4: Policy Impact - The introduction of the "1+6" policy and the establishment of the "Sci-Tech Growth Layer" aim to support unprofitable companies in high-tech sectors, balancing innovation support with market risk prevention [5][6]. - Since the policy's implementation, 15 new IPO applications have been accepted, including four from unprofitable companies, indicating a positive response to the new listing standards [6].

Core Viewpoint - The Sci-Tech Innovation Board (STAR Market) has successfully created a multi-path listing approach for unprofitable companies, allowing them to access capital markets without the traditional profit threshold, thus facilitating the transformation of R&D capabilities into operational performance and industrial value [1][2]. Group 1: Listing Standards - The STAR Market has five sets of listing standards, with the second to fifth sets not requiring profit, instead focusing on revenue scale combined with various factors such as R&D intensity, cash flow, and market capitalization [2]. - The second to fourth sets cater to "hard technology" companies with strong R&D capabilities, while the fifth set targets innovative companies with leading technologies but no commercialized products yet, based on market capitalization and R&D achievements [2][4]. Group 2: Performance of Unprofitable Companies - Among the 54 unprofitable companies listed, 40% have achieved profitability, with a total revenue of 1,745 billion yuan in 2024, marking a 24% year-on-year increase, and a net loss reduction of 36% [3]. - By the first half of 2025, these companies reported a revenue of 999 billion yuan, an 8% increase year-on-year, with a significant reduction in net loss by 70% [3]. Group 3: Industry Leaders and Innovations - Leading companies like BeiGene and Cambricon have achieved significant milestones, with BeiGene's new cancer drug generating over 10 billion yuan in half-year sales, and Baillie Gifford's ADC drug achieving record overseas licensing deals [3][4]. - In the semiconductor sector, companies like SMIC and Cambrian are driving innovation and breaking foreign monopolies, enhancing the self-sufficiency of the industry [4]. Group 4: Policy Support and Market Dynamics - The introduction of the "1+6" policy and the establishment of the "Sci-Tech Growth Layer" aim to support unprofitable companies in emerging fields like AI and commercial aerospace, balancing innovation support with market risk management [5][6]. - Since the policy's implementation, 15 new IPO applications have been accepted, including four from unprofitable companies, indicating a positive trend in capital market access for innovative firms [6].

Core Viewpoint - Conservative hybrid funds are designed for investors with a low to moderate risk profile, offering a mix of debt and equity investments to balance stability and growth potential [1] Fund Overview - ICICI Prudential Regular Savings Fund (IRSF) has consistently delivered debt-plus returns, achieving a compounded annual growth rate (CAGR) of 9.5% over the last 10 years [2] - The fund maintains an equity allocation of 15-24% over the past five years, adjusting according to market conditions, while the remainder is invested in debt instruments [2] Equity Strategy - The fund employs a dual strategy of top-down macroeconomic analysis and bottom-up contrarian stock picking, focusing on economic cycles and mean reversion [3] - Current sector allocations show significant overweight in life insurance and utilities, while consumer discretionary and capital goods are underweighted due to high valuations [4] Market Capitalization Bias - Approximately two-thirds of the equity allocation is in large-cap stocks, with 13% in large-caps, 3% in mid-caps, and 6% in small-caps [5] Debt Portfolio Management - The debt portfolio is dynamically managed, including government securities, AAA-rated corporate debt, and selective non-AAA papers to enhance yield [6] - The portfolio duration is moderate, with a Macaulay Duration of 1.25-3.5 years, and current allocations include 20% in government securities, 18% in AAA-rated corporates, and 30% in non-AAA papers [7] Non-AAA Debt Exposure - Non-AAA assets play a crucial role in boosting yield, with 4% in A-rated instruments and 26% in AA-rated holdings, while maintaining a conservative average maturity of 1-1.25 years [8] Performance Metrics - The fund's three-year rolling return analysis shows an average annualized return of 9.5%, outperforming the category average of 8.8% [10] - As of August 31, 2025, the fund's debt portfolio has a yield to maturity (YTM) of 7.4%, exceeding the category average of 6.9% [11] Risk Profile - The fund has an annualized standard deviation of 2.9%, lower than the category average of 3.5%, making it suitable for medium risk appetite investors with a minimum investment horizon of five years [12]